))
ONCOLOGY: Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
Archived series ("Inactive feed" status)
When?
This feed was archived on June 29, 2019 01:11 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 151341653 series 1024717
Content provided by Audio Medica. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Audio Journal of Oncology, December 10th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Oblimersen Extends Survival in Chronic Lymphocytic Leukemia SUSAN O'BRIEN, MD Anderson Cancer Center, Houston REFERENCE: ASH 2007 For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
…
continue reading
106 episodes
Share
